# Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

> **NCT00237718** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 385 (actual)

## Conditions studied

- End-stage Renal Disease

## Interventions

- **DRUG:** Alpha, gamma, beta, and delta (mixed) tocopherols
- **DRUG:** Alpha lipoic acid
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00237718
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2012-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237718, "Provision of Antioxidant Therapy in Hemodialysis (PATH) Study". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00237718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*